ARCHIVES

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

This article is from The Cancer Letter archive.

Vol. 30 No. 21 | May 21, 2004

Download PDF Visit The Full Archive

Related Articles

After Furlough, Blizzard, NCI Struggles to Clear Backlog and Resume Business

January 19, 1996

Dana-Farber Correction Plan Sent To State; Pharmacy Chief Resigns

June 9, 1995

In Brief: Calabresi: Rimer: Outstanding ”For NCAB Chair; board Should Maintain Strong Leadership Role

September 23, 1994

GAO Suggests No Limit On Indirect Costs But Ceiling On Total Costs

September 7, 1979

FDA Approves Folotyn For Peripheral T-Cell Lymphoma

September 25, 2009

DCT Board Approves Concept To Recomplete Data Management Contract

June 29, 1984